X

Trial Profile

A Phase Ib/II Trial of AK104 Plus Anlotinib in Patients With NSCLC

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cadonilimab (Primary) ; Catequentinib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Akeso Biopharma

Most Recent Events

18 Dec 2023 Results (n=69) assessing safety and efficacy of cadonilimab plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer published in the British Journal of Cancer
18 May 2022 Status changed from recruiting to active, no longer recruiting.
06 Jan 2022 Status changed from not yet recruiting to recruiting, according to a Akeso Biopharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com